# Jeroen Vangindertael

> Jeroen Vangindertael is a Series B investor at Ackermans & van Haaren backing Medical. See 2 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [Ackermans & van Haaren](https://shizune.co/investors/profile/ackermans-van-haaren)
- Location: Brussels, Belgium
- Total investments: 2
- Last investment: Jul 2024
- Lead investor: 100%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/in/jeroen-vangindertael-1ab574a0/?original_referer=https%3A%2F%2Fwww%2Egoogle%2Ecom%2F&originalSubdomain=be

Jeroen Vangindertael is a Series B investor at Ackermans & van Haaren in Brussels focused on Medical and Health Care. Jeroen Vangindertael is the Investment Manager at Ackermans & van Haaren.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Medical | 2 | 100% |
| Health Care | 2 | 100% |
| Therapeutics | 1 | 50% |
| Biotechnology | 1 | 50% |
| Pharmaceutical | 1 | 50% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| Belgium | 1 | 50% |
| The Netherlands | 1 | 50% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Confo Therapeutics | Confo Therapeutics is a drug discovery company building internal drug discovery programs on GPCRs addressing unmet medical need. Confo Therapeutics employs its proprietary CONFO technology to lock inherent unstable functional conformations of GPCRs as a superior starting point for drug discovery. CONFO body-stabilized active state conformations ofthese receptors disclose previously inaccessible structural features empowering the discovery of novel agonists for better therapeutic intervention. | $65.2M | Series B | Jul 26, 2024 |  |
| Vico Therapeutics | Vico Therapeutics is a developer of ribonucleic acid (RNA) modulating therapies for rare neurological disorders. The company discovers, develops, and delivers therapies for CNS disorders. Its initial focus is on SCA which is a subgroup of hereditary ataxia, HD which is a neurodegenerative disorder, and RTT-a neurodevelopmental disorder primarilyaffecting girls that enable clients with providing therapy for it.Vico Therapeutics was founded in 2019 by Luc Dochez, Josh Mandel-Brehm, Judith van Deutekom, and Gail Mandel and it is headquartered in Leiden, The Netherlands. | $72.1M | Series B | Jan 05, 2024 |  |

2 of 2 investments shown.

## Co-investors
- [Kurma Partners](https://shizune.co/investors/profile/kurma-life-science-partners) — VC Fund, 3 deals together
- [EQT Life Sciences](https://shizune.co/investors/profile/life-sciences-partners) — VC Fund, 2 deals together
- [BioGeneration Ventures](https://shizune.co/investors/profile/biogeneration-ventures) — VC Fund, 1 deal together
- [Capricorn Partners](https://shizune.co/investors/profile/capricorn-partners) — VC Fund, 1 deal together
- [Driehaus Capital Management](https://shizune.co/investors/profile/driehaus-capital-management) — VC Fund, 1 deal together
- [Droia Ventures](https://shizune.co/investors/profile/droia) — VC Fund, 1 deal together

## About Ackermans & van Haaren

VC Fund · Antwerpen, Belgium

Ackermans & van Haaren is a diversified group active in 5 segments: Marine Engineering & Infrastructure; Private Banking; Real Estate, Leisure & Senior Care; Energy & Resources; Development Capital. Marine Engineering & Infrastructure: DEME, one of the largest dredging companies in the world - Algemene Aannemingen Van Laere,a leading contractor in Belgium. Ackermans & van Haaren is an independent and diversified group aiming at creating shareholder value through long-term investments in a limited number of companies with growth potential on an international level.

5 contacts available at Ackermans & van Haaren.

| Name | Title | Profile |
| --- | --- | --- |
| Jeroen Vangindertael | Investment Manager | https://shizune.co/investors/profile/jeroen-vangindertael |
| Luc Bertrand | CEO | https://shizune.co/investors/profile/luc-bertrand |
| Matthias De Raeymaeker | Investment manager | https://shizune.co/investors/profile/matthias-de-raeymaeker |
| Philip Heylen | Business Development Manager | https://shizune.co/investors/profile/philip-heylen |
| Pierre Macharis | Non Executive Director | https://shizune.co/investors/profile/pierre-macharis |

## Similar investors

### Similar stage
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund
- [FJ Labs](https://shizune.co/investors/profile/fj-labs) — VC Fund

## FAQ

### What does Jeroen Vangindertael invest in?

Jeroen Vangindertael invests primarily in Medical, Health Care and Therapeutics startups, most often at Series B stage. Most of the 2 investments tracked by Shizune back companies in Belgium. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Jeroen Vangindertael last invest?

The most recent investment recorded for Jeroen Vangindertael closed in Jul 2024. Shizune tracks 2 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co